Login to Your Account

Probody building: Cytomx adds flex with Abbvie deal, gains up to $500M in CD71

By Randy Osborne
Staff Writer

Friday, April 22, 2016

CEO Sean McCarthy told BioWorld Today that Cytomx Therapeutics Inc.'s deals will be "increasingly strategic," structured for purposes of "not just bringing cash in the door," and the latest with Abbvie Inc. typifies what he's talking about.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription